https://stock.noler.com/us/stock/nabriva-therapeutics-plc https://stock.noler.com/us/stock/nabriva-therapeutics-plc/accounts-and-other-receivables-net-current https://stock.noler.com/us/stock/nabriva-therapeutics-plc/accounts-payable https://stock.noler.com/us/stock/nabriva-therapeutics-plc/accounts-receivable https://stock.noler.com/us/stock/nabriva-therapeutics-plc/accounts-receivable-gross https://stock.noler.com/us/stock/nabriva-therapeutics-plc/accrual-at-carrying-value https://stock.noler.com/us/stock/nabriva-therapeutics-plc/accrued-income-taxes-current https://stock.noler.com/us/stock/nabriva-therapeutics-plc/accrued-liabilities-current https://stock.noler.com/us/stock/nabriva-therapeutics-plc/accrued-professional-fees-current https://stock.noler.com/us/stock/nabriva-therapeutics-plc/accumulated-depreciation https://stock.noler.com/us/stock/nabriva-therapeutics-plc/additional-paid-in-capital-common-stock https://stock.noler.com/us/stock/nabriva-therapeutics-plc/allocated-share-based-compensation-expense https://stock.noler.com/us/stock/nabriva-therapeutics-plc/antidilutive-securities-excluded-from-computation-of-earnings-per-share-amount https://stock.noler.com/us/stock/nabriva-therapeutics-plc/aoci https://stock.noler.com/us/stock/nabriva-therapeutics-plc/available-for-sale-debt-accumulated-gross-unrealized-loss-before-tax https://stock.noler.com/us/stock/nabriva-therapeutics-plc/available-for-sale-debt-amortized-cost-basis https://stock.noler.com/us/stock/nabriva-therapeutics-plc/available-for-sale-debt-securities https://stock.noler.com/us/stock/nabriva-therapeutics-plc/basic-shares https://stock.noler.com/us/stock/nabriva-therapeutics-plc/buybacks-payments-for-repurchase-of-warrants https://stock.noler.com/us/stock/nabriva-therapeutics-plc/cash-and-cash-equivalents-change https://stock.noler.com/us/stock/nabriva-therapeutics-plc/cash-and-equivalents https://stock.noler.com/us/stock/nabriva-therapeutics-plc/cash-and-restricted-cash https://stock.noler.com/us/stock/nabriva-therapeutics-plc/cash-cash-equivalents-and-short-term-investments https://stock.noler.com/us/stock/nabriva-therapeutics-plc/cash-flow-breakdown https://stock.noler.com/us/stock/nabriva-therapeutics-plc/common-stock-no-par-value https://stock.noler.com/us/stock/nabriva-therapeutics-plc/common-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/nabriva-therapeutics-plc/common-stock-value https://stock.noler.com/us/stock/nabriva-therapeutics-plc/comprehensive-income https://stock.noler.com/us/stock/nabriva-therapeutics-plc/comprehensive-income-net-of-tax-including-portion-attributable-to-noncontrolling-interest https://stock.noler.com/us/stock/nabriva-therapeutics-plc/contract-liability https://stock.noler.com/us/stock/nabriva-therapeutics-plc/contract-with-customer-asset-net-current https://stock.noler.com/us/stock/nabriva-therapeutics-plc/contractual-obligation https://stock.noler.com/us/stock/nabriva-therapeutics-plc/contractual-obligation-due-after-fifth-year https://stock.noler.com/us/stock/nabriva-therapeutics-plc/contractual-obligation-due-in-fifth-year https://stock.noler.com/us/stock/nabriva-therapeutics-plc/contractual-obligation-due-in-fourth-year https://stock.noler.com/us/stock/nabriva-therapeutics-plc/contractual-obligation-due-in-next-twelve-months https://stock.noler.com/us/stock/nabriva-therapeutics-plc/contractual-obligation-due-in-second-year https://stock.noler.com/us/stock/nabriva-therapeutics-plc/contractual-obligation-due-in-third-year https://stock.noler.com/us/stock/nabriva-therapeutics-plc/contractual-obligation-future-minimum-payments-due-remainder-of-fiscal-year https://stock.noler.com/us/stock/nabriva-therapeutics-plc/cost-of-revenue https://stock.noler.com/us/stock/nabriva-therapeutics-plc/cost-of-revenue-2 https://stock.noler.com/us/stock/nabriva-therapeutics-plc/costs-and-expenses https://stock.noler.com/us/stock/nabriva-therapeutics-plc/cover-page-shares-outstanding https://stock.noler.com/us/stock/nabriva-therapeutics-plc/current-assets https://stock.noler.com/us/stock/nabriva-therapeutics-plc/current-federal-state-and-local-tax-expense-benefit https://stock.noler.com/us/stock/nabriva-therapeutics-plc/current-foreign-tax-expense-benefit https://stock.noler.com/us/stock/nabriva-therapeutics-plc/current-liabilities https://stock.noler.com/us/stock/nabriva-therapeutics-plc/current-portion-of-long-term-debt https://stock.noler.com/us/stock/nabriva-therapeutics-plc/debt-issued https://stock.noler.com/us/stock/nabriva-therapeutics-plc/debt-maturing-in-next-twelve-months https://stock.noler.com/us/stock/nabriva-therapeutics-plc/debt-maturing-in-year-five https://stock.noler.com/us/stock/nabriva-therapeutics-plc/debt-maturing-in-year-four https://stock.noler.com/us/stock/nabriva-therapeutics-plc/debt-maturing-in-year-three https://stock.noler.com/us/stock/nabriva-therapeutics-plc/debt-maturing-in-year-two https://stock.noler.com/us/stock/nabriva-therapeutics-plc/debt-maturing-remainder-of-fiscal-year https://stock.noler.com/us/stock/nabriva-therapeutics-plc/debt-repaid https://stock.noler.com/us/stock/nabriva-therapeutics-plc/deferred-foreign-income-tax-expense-benefit https://stock.noler.com/us/stock/nabriva-therapeutics-plc/deferred-income-tax-expense-benefit https://stock.noler.com/us/stock/nabriva-therapeutics-plc/deferred-income-tax-liabilities https://stock.noler.com/us/stock/nabriva-therapeutics-plc/deferred-tax-assets-gross https://stock.noler.com/us/stock/nabriva-therapeutics-plc/deferred-tax-assets-investment-in-subsidiaries https://stock.noler.com/us/stock/nabriva-therapeutics-plc/deferred-tax-assets-liabilities-net https://stock.noler.com/us/stock/nabriva-therapeutics-plc/deferred-tax-assets-liabilities-net-noncurrent https://stock.noler.com/us/stock/nabriva-therapeutics-plc/deferred-tax-assets-net https://stock.noler.com/us/stock/nabriva-therapeutics-plc/deferred-tax-assets-operating-loss-carryforwards https://stock.noler.com/us/stock/nabriva-therapeutics-plc/deferred-tax-assets-stock-compensation https://stock.noler.com/us/stock/nabriva-therapeutics-plc/deferred-tax-assets-tax-deferred-expense-reserves-and-accruals https://stock.noler.com/us/stock/nabriva-therapeutics-plc/deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/nabriva-therapeutics-plc/deferred-tax-liabilities-financing-arrangements https://stock.noler.com/us/stock/nabriva-therapeutics-plc/deferred-tax-liabilities-property-plant-and-equipment https://stock.noler.com/us/stock/nabriva-therapeutics-plc/defined-benefit-plan-assumptions-used-calculating-benefit-obligation-discount-rate https://stock.noler.com/us/stock/nabriva-therapeutics-plc/defined-benefit-plan-assumptions-used-calculating-benefit-obligation-rate-of-compensation-increase https://stock.noler.com/us/stock/nabriva-therapeutics-plc/deposits-assets-noncurrent https://stock.noler.com/us/stock/nabriva-therapeutics-plc/depreciation-and-amortization https://stock.noler.com/us/stock/nabriva-therapeutics-plc/diluted-shares https://stock.noler.com/us/stock/nabriva-therapeutics-plc/earnings-per-share-basic-and-diluted https://stock.noler.com/us/stock/nabriva-therapeutics-plc/effect-of-exchange-rate-on-cash-and-cash-equivalents https://stock.noler.com/us/stock/nabriva-therapeutics-plc/effect-of-exchange-rate-on-cash-and-restricted-cash https://stock.noler.com/us/stock/nabriva-therapeutics-plc/effective-tax-rate https://stock.noler.com/us/stock/nabriva-therapeutics-plc/employee-related-liabilities-current https://stock.noler.com/us/stock/nabriva-therapeutics-plc/eps https://stock.noler.com/us/stock/nabriva-therapeutics-plc/eps-basic https://stock.noler.com/us/stock/nabriva-therapeutics-plc/exchange-rate-effect-on-cash https://stock.noler.com/us/stock/nabriva-therapeutics-plc/fair-value-assets-level-1-to-level-2-transfers-amount https://stock.noler.com/us/stock/nabriva-therapeutics-plc/fair-value-assets-level-2-to-level-1-transfers-amount https://stock.noler.com/us/stock/nabriva-therapeutics-plc/fair-value-liabilities-level-1-to-level-2-transfers-amount https://stock.noler.com/us/stock/nabriva-therapeutics-plc/fair-value-liabilities-level-2-to-level-1-transfers-amount https://stock.noler.com/us/stock/nabriva-therapeutics-plc/fair-value-measurement-with-unobservable-inputs-reconciliations-recurring-basis-liability-value https://stock.noler.com/us/stock/nabriva-therapeutics-plc/financing-cash-flow https://stock.noler.com/us/stock/nabriva-therapeutics-plc/foreign-currency-transaction-gain-before-tax https://stock.noler.com/us/stock/nabriva-therapeutics-plc/foreign-currency-transaction-loss-before-tax https://stock.noler.com/us/stock/nabriva-therapeutics-plc/foreign-pretax-income https://stock.noler.com/us/stock/nabriva-therapeutics-plc/form-d-stocks https://stock.noler.com/us/stock/nabriva-therapeutics-plc/gains-losses-on-extinguishment-of-debt https://stock.noler.com/us/stock/nabriva-therapeutics-plc/general-and-administrative-expense https://stock.noler.com/us/stock/nabriva-therapeutics-plc/grants-receivable-current https://stock.noler.com/us/stock/nabriva-therapeutics-plc/income-tax https://stock.noler.com/us/stock/nabriva-therapeutics-plc/income-taxes-paid https://stock.noler.com/us/stock/nabriva-therapeutics-plc/income-taxes-paid-2 https://stock.noler.com/us/stock/nabriva-therapeutics-plc/increase-decrease-in-accounts-payable https://stock.noler.com/us/stock/nabriva-therapeutics-plc/increase-decrease-in-accrued-liabilities https://stock.noler.com/us/stock/nabriva-therapeutics-plc/increase-decrease-in-deferred-revenue https://stock.noler.com/us/stock/nabriva-therapeutics-plc/increase-decrease-in-income-taxes-payable-net-of-income-taxes-receivable https://stock.noler.com/us/stock/nabriva-therapeutics-plc/increase-decrease-in-inventories https://stock.noler.com/us/stock/nabriva-therapeutics-plc/increase-decrease-in-other-noncurrent-assets https://stock.noler.com/us/stock/nabriva-therapeutics-plc/increase-decrease-in-other-noncurrent-liabilities https://stock.noler.com/us/stock/nabriva-therapeutics-plc/increase-decrease-in-other-receivables https://stock.noler.com/us/stock/nabriva-therapeutics-plc/insider-transactions-other https://stock.noler.com/us/stock/nabriva-therapeutics-plc/insider-transactions-stock-options https://stock.noler.com/us/stock/nabriva-therapeutics-plc/insider-transactions-stock-units https://stock.noler.com/us/stock/nabriva-therapeutics-plc/intangible-assets-net-excluding-goodwill https://stock.noler.com/us/stock/nabriva-therapeutics-plc/interest-expense https://stock.noler.com/us/stock/nabriva-therapeutics-plc/interest-income-expense-net https://stock.noler.com/us/stock/nabriva-therapeutics-plc/interest-paid https://stock.noler.com/us/stock/nabriva-therapeutics-plc/interest-paid-net https://stock.noler.com/us/stock/nabriva-therapeutics-plc/inventory https://stock.noler.com/us/stock/nabriva-therapeutics-plc/inventory-adjustments https://stock.noler.com/us/stock/nabriva-therapeutics-plc/inventory-finished-goods https://stock.noler.com/us/stock/nabriva-therapeutics-plc/inventory-gross https://stock.noler.com/us/stock/nabriva-therapeutics-plc/inventory-raw-materials https://stock.noler.com/us/stock/nabriva-therapeutics-plc/inventory-valuation-reserves https://stock.noler.com/us/stock/nabriva-therapeutics-plc/inventory-work-in-process https://stock.noler.com/us/stock/nabriva-therapeutics-plc/inventory-write-down https://stock.noler.com/us/stock/nabriva-therapeutics-plc/investing-cash-flow https://stock.noler.com/us/stock/nabriva-therapeutics-plc/investment-income-interest https://stock.noler.com/us/stock/nabriva-therapeutics-plc/lease-and-rental-expense https://stock.noler.com/us/stock/nabriva-therapeutics-plc/lessee-operating-lease-liability-payments-remainder-of-fiscal-year https://stock.noler.com/us/stock/nabriva-therapeutics-plc/lessee-operating-lease-liability-undiscounted-excess-amount https://stock.noler.com/us/stock/nabriva-therapeutics-plc/level-3-liability-gain-loss-included-in-earnings https://stock.noler.com/us/stock/nabriva-therapeutics-plc/level-3-liability-settlements https://stock.noler.com/us/stock/nabriva-therapeutics-plc/liabilities-noncurrent https://stock.noler.com/us/stock/nabriva-therapeutics-plc/long-term-debt https://stock.noler.com/us/stock/nabriva-therapeutics-plc/loss-in-period https://stock.noler.com/us/stock/nabriva-therapeutics-plc/minority-interest https://stock.noler.com/us/stock/nabriva-therapeutics-plc/net-cash-from-financing-activities https://stock.noler.com/us/stock/nabriva-therapeutics-plc/net-cash-from-investing-activities https://stock.noler.com/us/stock/nabriva-therapeutics-plc/net-cash-from-operating-activities https://stock.noler.com/us/stock/nabriva-therapeutics-plc/net-change-in-cash https://stock.noler.com/us/stock/nabriva-therapeutics-plc/net-income https://stock.noler.com/us/stock/nabriva-therapeutics-plc/net-income-loss-available-to-common-stockholders-basic https://stock.noler.com/us/stock/nabriva-therapeutics-plc/net-income-loss-available-to-common-stockholders-diluted https://stock.noler.com/us/stock/nabriva-therapeutics-plc/nontrade-receivables https://stock.noler.com/us/stock/nabriva-therapeutics-plc/nontrade-receivables-current https://stock.noler.com/us/stock/nabriva-therapeutics-plc/nontrade-receivables-noncurrent https://stock.noler.com/us/stock/nabriva-therapeutics-plc/number-of-operating-segments https://stock.noler.com/us/stock/nabriva-therapeutics-plc/oci-foreign-currency-transaction-and-translation-gain-loss-arising-net-of-tax https://stock.noler.com/us/stock/nabriva-therapeutics-plc/oci-net-of-tax https://stock.noler.com/us/stock/nabriva-therapeutics-plc/oci-net-of-tax-2 https://stock.noler.com/us/stock/nabriva-therapeutics-plc/oci-unrealized-holding-gain-loss-on-securities-arising-net-of-tax https://stock.noler.com/us/stock/nabriva-therapeutics-plc/operating-cash-flow https://stock.noler.com/us/stock/nabriva-therapeutics-plc/operating-expenses https://stock.noler.com/us/stock/nabriva-therapeutics-plc/operating-income https://stock.noler.com/us/stock/nabriva-therapeutics-plc/operating-lease-expense https://stock.noler.com/us/stock/nabriva-therapeutics-plc/operating-lease-liability https://stock.noler.com/us/stock/nabriva-therapeutics-plc/operating-lease-payments https://stock.noler.com/us/stock/nabriva-therapeutics-plc/operating-lease-payments-due https://stock.noler.com/us/stock/nabriva-therapeutics-plc/operating-lease-payments-due-2 https://stock.noler.com/us/stock/nabriva-therapeutics-plc/operating-lease-payments-due-current https://stock.noler.com/us/stock/nabriva-therapeutics-plc/operating-lease-payments-due-in-five-years https://stock.noler.com/us/stock/nabriva-therapeutics-plc/operating-lease-payments-due-in-four-years https://stock.noler.com/us/stock/nabriva-therapeutics-plc/operating-lease-payments-due-in-three-years https://stock.noler.com/us/stock/nabriva-therapeutics-plc/operating-lease-payments-due-in-two-years https://stock.noler.com/us/stock/nabriva-therapeutics-plc/operating-lease-payments-due-next-twelve-months https://stock.noler.com/us/stock/nabriva-therapeutics-plc/operating-lease-payments-due-thereafter https://stock.noler.com/us/stock/nabriva-therapeutics-plc/operating-lease-payments-due-year-five https://stock.noler.com/us/stock/nabriva-therapeutics-plc/operating-lease-payments-due-year-four https://stock.noler.com/us/stock/nabriva-therapeutics-plc/operating-lease-payments-due-year-three https://stock.noler.com/us/stock/nabriva-therapeutics-plc/operating-lease-payments-due-year-two https://stock.noler.com/us/stock/nabriva-therapeutics-plc/operating-lease-right-of-use-asset-amortization-expense https://stock.noler.com/us/stock/nabriva-therapeutics-plc/operating-lease-weighted-average-discount-rate-percent https://stock.noler.com/us/stock/nabriva-therapeutics-plc/operating-loss-carryforwards https://stock.noler.com/us/stock/nabriva-therapeutics-plc/other-accrued-liabilities-current https://stock.noler.com/us/stock/nabriva-therapeutics-plc/other-commitment https://stock.noler.com/us/stock/nabriva-therapeutics-plc/other-commitment-due-after-fifth-year https://stock.noler.com/us/stock/nabriva-therapeutics-plc/other-commitment-due-in-fifth-year https://stock.noler.com/us/stock/nabriva-therapeutics-plc/other-commitment-due-in-fourth-year https://stock.noler.com/us/stock/nabriva-therapeutics-plc/other-commitment-due-in-next-twelve-months https://stock.noler.com/us/stock/nabriva-therapeutics-plc/other-commitment-due-in-second-year https://stock.noler.com/us/stock/nabriva-therapeutics-plc/other-commitment-due-in-third-year https://stock.noler.com/us/stock/nabriva-therapeutics-plc/other-commitments-future-minimum-payments-remainder-of-fiscal-year https://stock.noler.com/us/stock/nabriva-therapeutics-plc/other-income https://stock.noler.com/us/stock/nabriva-therapeutics-plc/other-noncash-income-expense https://stock.noler.com/us/stock/nabriva-therapeutics-plc/other-noncurrent-assets https://stock.noler.com/us/stock/nabriva-therapeutics-plc/other-noncurrent-liabilities https://stock.noler.com/us/stock/nabriva-therapeutics-plc/other-nonoperating-income-expense https://stock.noler.com/us/stock/nabriva-therapeutics-plc/other-operating-activities-cash-flow-statement https://stock.noler.com/us/stock/nabriva-therapeutics-plc/other-prepaid-expense-current https://stock.noler.com/us/stock/nabriva-therapeutics-plc/other-receivables-net-current https://stock.noler.com/us/stock/nabriva-therapeutics-plc/paid-in-capital-convertible-debt-with-conversion-feature https://stock.noler.com/us/stock/nabriva-therapeutics-plc/paid-in-capital-other https://stock.noler.com/us/stock/nabriva-therapeutics-plc/paid-in-capital-share-based-compensation-stock-options-requisite-service-period-recognition https://stock.noler.com/us/stock/nabriva-therapeutics-plc/paid-in-capital-shares-issued-issuance-costs https://stock.noler.com/us/stock/nabriva-therapeutics-plc/payments-of-debt-issuance-costs https://stock.noler.com/us/stock/nabriva-therapeutics-plc/payments-of-stock-issuance-costs https://stock.noler.com/us/stock/nabriva-therapeutics-plc/payments-to-acquire-available-for-sale-debt https://stock.noler.com/us/stock/nabriva-therapeutics-plc/payments-to-acquire-available-for-sale-securities https://stock.noler.com/us/stock/nabriva-therapeutics-plc/payments-to-acquire-other-investments https://stock.noler.com/us/stock/nabriva-therapeutics-plc/payments-to-acquire-productive-assets https://stock.noler.com/us/stock/nabriva-therapeutics-plc/payments-to-acquire-restricted-certificates-of-deposit https://stock.noler.com/us/stock/nabriva-therapeutics-plc/preferred-shares-facts https://stock.noler.com/us/stock/nabriva-therapeutics-plc/preferred-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/nabriva-therapeutics-plc/preferred-stock-shares-authorized https://stock.noler.com/us/stock/nabriva-therapeutics-plc/preferred-stock-shares-issued https://stock.noler.com/us/stock/nabriva-therapeutics-plc/preferred-stock-shares-outstanding https://stock.noler.com/us/stock/nabriva-therapeutics-plc/prepaid-expense-current https://stock.noler.com/us/stock/nabriva-therapeutics-plc/pretax-income https://stock.noler.com/us/stock/nabriva-therapeutics-plc/pretax-income-domestic https://stock.noler.com/us/stock/nabriva-therapeutics-plc/pretax-income-minority-interest-and-income-loss-from-equity-method-investments https://stock.noler.com/us/stock/nabriva-therapeutics-plc/proceeds-from-convertible-debt https://stock.noler.com/us/stock/nabriva-therapeutics-plc/proceeds-from-issuance-initial-public-offering https://stock.noler.com/us/stock/nabriva-therapeutics-plc/proceeds-from-issuance-of-private-placement https://stock.noler.com/us/stock/nabriva-therapeutics-plc/proceeds-from-issuance-of-senior-long-term-debt https://stock.noler.com/us/stock/nabriva-therapeutics-plc/proceeds-from-issuance-or-sale-of-equity https://stock.noler.com/us/stock/nabriva-therapeutics-plc/proceeds-from-payments-for-other-financing-activities https://stock.noler.com/us/stock/nabriva-therapeutics-plc/proceeds-from-repayment-of-loans-by-employee-stock-ownership-plans https://stock.noler.com/us/stock/nabriva-therapeutics-plc/proceeds-from-repayments-of-other-long-term-debt https://stock.noler.com/us/stock/nabriva-therapeutics-plc/proceeds-from-sale-maturity-and-collections-of-investments https://stock.noler.com/us/stock/nabriva-therapeutics-plc/proceeds-from-sale-of-available-for-sale-debt https://stock.noler.com/us/stock/nabriva-therapeutics-plc/proceeds-from-sale-of-available-for-sale-securities https://stock.noler.com/us/stock/nabriva-therapeutics-plc/proceeds-from-sale-of-property-plant-and-equipment https://stock.noler.com/us/stock/nabriva-therapeutics-plc/proceeds-from-stock-issued https://stock.noler.com/us/stock/nabriva-therapeutics-plc/proceeds-from-stock-options-exercised https://stock.noler.com/us/stock/nabriva-therapeutics-plc/proceeds-from-warrant-exercises https://stock.noler.com/us/stock/nabriva-therapeutics-plc/profit-loss https://stock.noler.com/us/stock/nabriva-therapeutics-plc/property-plant-and-equipment-gross https://stock.noler.com/us/stock/nabriva-therapeutics-plc/property-plant-equipment https://stock.noler.com/us/stock/nabriva-therapeutics-plc/public-float https://stock.noler.com/us/stock/nabriva-therapeutics-plc/purchase-obligation https://stock.noler.com/us/stock/nabriva-therapeutics-plc/purchase-obligation-due-after-fifth-year https://stock.noler.com/us/stock/nabriva-therapeutics-plc/purchase-obligation-due-in-fifth-year https://stock.noler.com/us/stock/nabriva-therapeutics-plc/purchase-obligation-due-in-fourth-year https://stock.noler.com/us/stock/nabriva-therapeutics-plc/purchase-obligation-due-in-next-twelve-months https://stock.noler.com/us/stock/nabriva-therapeutics-plc/purchase-obligation-due-in-second-year https://stock.noler.com/us/stock/nabriva-therapeutics-plc/purchase-obligation-due-in-third-year https://stock.noler.com/us/stock/nabriva-therapeutics-plc/purchase-obligation-future-minimum-payments-remainder-of-fiscal-year https://stock.noler.com/us/stock/nabriva-therapeutics-plc/reclassification-from-aoci-current-period-net-of-tax-attributable-to-parent https://stock.noler.com/us/stock/nabriva-therapeutics-plc/research-and-development https://stock.noler.com/us/stock/nabriva-therapeutics-plc/research-and-development-in-process https://stock.noler.com/us/stock/nabriva-therapeutics-plc/restricted-cash https://stock.noler.com/us/stock/nabriva-therapeutics-plc/restructuring-costs https://stock.noler.com/us/stock/nabriva-therapeutics-plc/restructuring-reserve-current https://stock.noler.com/us/stock/nabriva-therapeutics-plc/retained-earnings https://stock.noler.com/us/stock/nabriva-therapeutics-plc/revenue https://stock.noler.com/us/stock/nabriva-therapeutics-plc/revenue-from-contract-with-customer-excluding-assessed-tax https://stock.noler.com/us/stock/nabriva-therapeutics-plc/revenue-from-grants https://stock.noler.com/us/stock/nabriva-therapeutics-plc/right-of-use-asset-obtained-in-exchange-for-operating-lease-liability https://stock.noler.com/us/stock/nabriva-therapeutics-plc/sale-of-stock-consideration-received-on-transaction https://stock.noler.com/us/stock/nabriva-therapeutics-plc/sga-expense https://stock.noler.com/us/stock/nabriva-therapeutics-plc/shareholders-equity https://stock.noler.com/us/stock/nabriva-therapeutics-plc/shares-authorized https://stock.noler.com/us/stock/nabriva-therapeutics-plc/shares-issued https://stock.noler.com/us/stock/nabriva-therapeutics-plc/shares-issued-price-per-share https://stock.noler.com/us/stock/nabriva-therapeutics-plc/short-term-investments https://stock.noler.com/us/stock/nabriva-therapeutics-plc/short-term-lease-cost https://stock.noler.com/us/stock/nabriva-therapeutics-plc/stock-award-fair-value-assumptions-expected-dividend-rate https://stock.noler.com/us/stock/nabriva-therapeutics-plc/stock-award-fair-value-assumptions-expected-volatility-rate https://stock.noler.com/us/stock/nabriva-therapeutics-plc/stock-award-fair-value-assumptions-risk-free-interest-rate https://stock.noler.com/us/stock/nabriva-therapeutics-plc/stock-based-compensation https://stock.noler.com/us/stock/nabriva-therapeutics-plc/stock-issued-new-shares-sold https://stock.noler.com/us/stock/nabriva-therapeutics-plc/stock-issued-shares-issued-value-conversion-of-convertible-securities https://stock.noler.com/us/stock/nabriva-therapeutics-plc/stock-issued-shares-issued-value-conversion-of-units https://stock.noler.com/us/stock/nabriva-therapeutics-plc/stock-issued-shares-issued-value-espp https://stock.noler.com/us/stock/nabriva-therapeutics-plc/stock-issued-shares-issued-value-other https://stock.noler.com/us/stock/nabriva-therapeutics-plc/stock-issued-shares-issued-value-restricted-stock-award-net-of-forfeitures https://stock.noler.com/us/stock/nabriva-therapeutics-plc/stock-issued-shares-issued-value-stock-options-exercised https://stock.noler.com/us/stock/nabriva-therapeutics-plc/stock-issued-value-of-shares-issued-for-acquisitions https://stock.noler.com/us/stock/nabriva-therapeutics-plc/stock-split-ratio https://stock.noler.com/us/stock/nabriva-therapeutics-plc/stockholders-equity-including-portion-attributable-to-noncontrolling-interest https://stock.noler.com/us/stock/nabriva-therapeutics-plc/tax-rate-reconciliation-at-federal-statutory-income-tax-rate https://stock.noler.com/us/stock/nabriva-therapeutics-plc/tax-rate-reconciliation-change-in-deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/nabriva-therapeutics-plc/tax-rate-reconciliation-foreign-income-tax-rate-differential https://stock.noler.com/us/stock/nabriva-therapeutics-plc/tax-rate-reconciliation-nondeductible-expense https://stock.noler.com/us/stock/nabriva-therapeutics-plc/tax-rate-reconciliation-nondeductible-expense-impairment-losses https://stock.noler.com/us/stock/nabriva-therapeutics-plc/tax-rate-reconciliation-nondeductible-expense-research-and-development https://stock.noler.com/us/stock/nabriva-therapeutics-plc/tax-rate-reconciliation-other-adjustments https://stock.noler.com/us/stock/nabriva-therapeutics-plc/tax-rate-reconciliation-tax-credits https://stock.noler.com/us/stock/nabriva-therapeutics-plc/tax-rate-reconciliation-tax-exempt-income https://stock.noler.com/us/stock/nabriva-therapeutics-plc/temporary-equity-accretion-to-redemption-value https://stock.noler.com/us/stock/nabriva-therapeutics-plc/temporary-equity-accretion-to-redemption-value-adjustment https://stock.noler.com/us/stock/nabriva-therapeutics-plc/temporary-equity-carrying-amount-including-portion-attributable-to-noncontrolling-interests https://stock.noler.com/us/stock/nabriva-therapeutics-plc/temporary-equity-foreign-currency-translation-adjustments https://stock.noler.com/us/stock/nabriva-therapeutics-plc/temporary-equity-shares-issued-value-new-issues https://stock.noler.com/us/stock/nabriva-therapeutics-plc/total-assets https://stock.noler.com/us/stock/nabriva-therapeutics-plc/total-liabilities https://stock.noler.com/us/stock/nabriva-therapeutics-plc/total-liabilities-and-equity https://stock.noler.com/us/stock/nabriva-therapeutics-plc/total-long-term-debt https://stock.noler.com/us/stock/nabriva-therapeutics-plc/treasury-stock-common-shares https://stock.noler.com/us/stock/nabriva-therapeutics-plc/treasury-stock-common-value https://stock.noler.com/us/stock/nabriva-therapeutics-plc/unrecognized-tax-benefits https://stock.noler.com/us/stock/nabriva-therapeutics-plc/valuation-allowances-and-reserves-balance https://stock.noler.com/us/stock/nabriva-therapeutics-plc/value-added-tax-receivable-current https://stock.noler.com/us/stock/nabriva-therapeutics-plc/weighted-average-number-of-share-outstanding-basic-and-diluted https://stock.noler.com/us/stock/nabriva-therapeutics-plc/weighted-average-number-of-shares-treasury-stock